Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N, Takeshita A, Nakaseko C, Dobashi N, Fujita H, Kiyoi H, Kobayashi Y, Sakura T, Yahagi Y, Shigeno K, Ohwada C, Miyazaki Y, Ohtake S, Miyawaki S, Naoe T, Ohnishi K; Japan Adult Leukemia Study Group. Usui N, et al. Among authors: ohtake s. Cancer Sci. 2011 Jul;102(7):1358-65. doi: 10.1111/j.1349-7006.2011.01957.x. Epub 2011 May 18. Cancer Sci. 2011. PMID: 21585619 Free article. Clinical Trial.
Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.
Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R. Asou N, et al. Among authors: ohtake s. J Clin Oncol. 1998 Jan;16(1):78-85. doi: 10.1200/JCO.1998.16.1.78. J Clin Oncol. 1998. PMID: 9440726
A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group.
Ohnishi K, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Hirashima K, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Ohno R. Ohnishi K, et al. Among authors: ohtake s. Leuk Res. 1998 Sep;22(9):779-86. doi: 10.1016/s0145-2126(98)00082-4. Leuk Res. 1998. PMID: 9716008 Clinical Trial.
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R, et al. Miyawaki S, et al. Among authors: ohtake s. Int J Hematol. 1999 Aug;70(2):97-104. Int J Hematol. 1999. PMID: 10497848 Clinical Trial.
Multicenter prospective study of interferon-alpha versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia: a preliminary analysis.
Ohnishi K, Ino T, Kishimoto Y, Usui N, Shimazaki C, Ohtake S, Taguchi H, Kusumoto S, Kuriyama K, Hotta T, Ohno R. Ohnishi K, et al. Among authors: ohtake s. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S59-64. doi: 10.1007/s002800100307. Cancer Chemother Pharmacol. 2001. PMID: 11587369 Clinical Trial.
Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study.
Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F, Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M, Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama H, Nakamura Y, Ohshima T, Ohno R. Takeuchi J, et al. Among authors: ohtake s. Leukemia. 2002 Jul;16(7):1259-66. doi: 10.1038/sj.leu.2402526. Leukemia. 2002. PMID: 12094249 Clinical Trial.
Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study.
Miyazaki Y, Kuriyama K, Miyawaki S, Ohtake S, Sakamaki H, Matsuo T, Emi N, Kobayashi T, Matsushima T, Shinagawa K, Ohno R, Tomonaga M; Japan Adult Leukaemia Study Group. Miyazaki Y, et al. Among authors: ohtake s. Br J Haematol. 2003 Jan;120(1):56-62. doi: 10.1046/j.1365-2141.2003.03981.x. Br J Haematol. 2003. PMID: 12492577 Free article.
Multicenter prospective study of interferon alpha versus allogeneic stem cell transplantation for patients with new diagnoses of chronic myelogenous leukemia.
Ohnishi K, Ino A, Kishimoto Y, Usui N, Shimazaki C, Ohtake S, Taguchi H, Yagasaki F, Tomonaga M, Hotta T, Ohno R; Japan Adult Leukemia Study Group. Ohnishi K, et al. Among authors: ohtake s. Int J Hematol. 2004 May;79(4):345-53. doi: 10.1532/ijh97.03160. Int J Hematol. 2004. PMID: 15218963 Clinical Trial.
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, Yagasaki F, Kawai Y, Miyawaki S, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group. Towatari M, et al. Among authors: ohtake s. Blood. 2004 Dec 1;104(12):3507-12. doi: 10.1182/blood-2004-04-1389. Epub 2004 Aug 17. Blood. 2004. PMID: 15315963 Free article. Clinical Trial.
444 results